NCT07189728View on ClinicalTrials.gov

The MagnaSafe-2 Registry: Assessing the Risks of Magnetic Resonance Imaging in Three Patient Groups

Not yet recruitingOBSERVATIONAL
Enrollment

1,500

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

January 1, 2031

Study Completion Date

January 1, 2031

Conditions
PacemakersMRI ImagingImplantable Cardioverter Defibrillator (ICD)
Interventions
DIAGNOSTIC_TEST

MRI

The MagnaSafe-2 Registry is designed to determine the risks of MRI in patients with limited MRI access not previously addressed in peer-reviewed literature and to improve access for approximately 70% of whom are predicted to have a future clinical need for MRI.

All Listed Sponsors
lead

The Scripps Research Institute

OTHER

NCT07189728 - The MagnaSafe-2 Registry: Assessing the Risks of Magnetic Resonance Imaging in Three Patient Groups | Biotech Hunter | Biotech Hunter